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Introduction
Substance	abuse	problems	represent	a	significant	public mental health issue for adolescents in the 
United	States,	with	23%	of	youth	having	developed	
a substance use disorder by the age of 18.1 Child-
hood mental health problems increase the overall 
risk	for	developing	adolescent-onset	substance	use	
disorders. Conversely, adolescent substance misuse 
increases	the	risk	of	developing	co-occurring	men-
tal	health	problems,	and	the	co-occurrence	mental	
health and substance use problems complicates clin-




mental health problems that could—and should—
be included in the deployment of comprehensive 
child and adolescent behavioral health services.
Epidemiology
There is rich literature regarding the epidemiology 
of substance use problems among adolescents. One 
of	the	most	recent	rigorous	efforts	is	the	National 
































disorders and other mental disorders reported in 15 












The rates of comorbidity are higher in treatment set-
tings.	For	example,	Aarons	et	al.6	found	that	40.8%	
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of substance use disorders.5	Protective	factors	include	
social	skills,	engagement	in	recreational	activities,	
having	a	non-parental	adult	role	model,	and	religious	
involvement.8 It is also notable that substance use dis-
orders, especially during adolescence, are associated 
with	a	greater	risk	of	developing	mental	health	prob-





than	whites	and	Hispanics.1 Studies of American In-




for adults over 21 is already having impacts on ado-










regarding its health impacts on youth.14
Finally,	despite	the	long-standing	recognition	of	ado-
lescent	substance	use	as	a	significant	public	health	
problem, access to care remains severely limited. In 
the	NCS-A,	only	15.4%	of	adolescents	with	substance	
use disorders received substance abuse services.2
Prevention
There	are	3	types	of	prevention	programs	cited	in	the	







































consequences of drugs and alcohol. This program 
is	intended	to	be	delivered	starting	in	the	seventh	
grade,	with	booster	sessions	in	subsequent	years	(10	










delivered using 12 sessions.17,22

































(SUD). Results from a recently completed pilot study 
provide	empirical	support	for	this	conjecture.27 The 
study	adapted	an	existing	16-week	evidence-based	

























goal of these more comprehensive assessments is to 
gain a clearer understanding of the nature and sever-
ity of the substance problem. They may also gather 
relevant	biopsychosocial	information,	establishing	an	











Evidence-Based Interventions For 
Adolescents With Substance Use  
Disorders (SUD)
Evidence-Based Psychosocial/Behavioral Treatments 


























































•	 Adolescent Drug Abuse Diagnosis (ADAD)
•	 Adolescent Drug Involvement Scale (ADIS)
•	 Adolescent Alcohol and Drug Involvement Scale (AADIS)
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Summary And Recommendations  
For Clinical Practice
Research in the past decade has increased our under-















N-Acetylcysteine	(NAC) Cannabis Use Disorder X	
































repeated measures to enable treatment programs to 





























































developing enhanced clinical training programs, and 
establishing	clinical	competency	and	credentialing	cri-














substance abuse and mental health problems. 
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